How Mammalian Cells Acquire Copper: An Essential but Potentially Toxic Metal  by Kaplan, Jack H. & Maryon, Edward B.
Biophysical Journal Volume 110 January 2016 7–13 7Biophysical PerspectiveHow Mammalian Cells Acquire Copper: An Essential but Potentially Toxic
MetalJack H. Kaplan1,* and Edward B. Maryon1
1Department of Biochemistry and Molecular Genetics, University of Illinois College of Medicine, Chicago, IllinoisABSTRACT Cu is an essential micronutrient, and its role in an array of critical physiological processes is receiving increasing
attention. Among these are wound healing, angiogenesis, protection against reactive oxygen species, neurotransmitter synthe-
sis, modulation of normal cell and tumor growth, and many others. Free Cu is absent inside cells, and a network of proteins has
evolved to deliver this essential, but potentially toxic, metal ion to its intracellular target sites following uptake. Although the total
body content is low (~100 mg), dysfunction of proteins involved in Cu homeostasis results in several well-characterized human
disease states. The initial step in cellular Cu handling is its transport across the plasma membrane, a subject of study for only
about the last 25 years. This review focuses on the initial step in Cu homeostasis, the properties of the major protein, hCTR1,
that mediates Cu uptake, and the status of our understanding of this highly specialized transport system. Although a high-res-
olution structure of the protein is still lacking, an array of biochemical and biophysical studies have provided a picture of how
hCTR1 mediates Cu(I) transport and how Cu is delivered to the proteins in the intracellular milieu. Recent studies provide
evidence that the transporter also plays a key protective role in the regulation of cellular Cu via regulatory endocytosis, lowering
its surface expression, in response to elevated Cu loads.Cu is used as a cofactor in numerous enzymatic mecha-
nisms. Many of these use the dual redox states of Cu(I)
and Cu(II) and their relatively facile interconversion, under
physiological conditions, in oxidation-reduction cycles. Ex-
amples of cellular processes that depend on Cu include,
mitochondrial aerobic metabolism as the central metal ion
of cytochrome C oxidase; as a cofactor for dopamine b-hy-
droxylase in the biosynthesis of neurotransmitters and for
peptidylglycine a-amidating monooxygenase in neuropep-
tide biosynthesis; in the important protective role of Cu,
Zn-superoxide dismutase (SOD) against reactive oxygen
species; and in Cu-dependent lysyl oxidase in cross-linking
the collagen in extracellular matrix and connective tissue,
during wound healing, metastasis, and growth. Paradoxi-
cally, Cu can be a potent inhibitor of many cellular enzymes.
Cu ions react promiscuously with a wide array of protein
side chains that contain sulfur, nitrogen, and oxygen. In
addition, the production of reactive oxygen species by Cu
adds another damaging consequence to Cu elevation. How
then do cells navigate the critical path between the Scylla
of Cu deficiency and the Charybdis of toxicity?
We are familiar with the transport of the major compo-
nents of physiological media, Na, K, Cl, etc. It is apparent
that the concentration of free Cu ions in cells is undetectable
and estimated to be <1018 M (1). Among the conse-
quences of this are that considerations of the energetics ofSubmitted June 19, 2015, and accepted for publication November 9, 2015.
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tions of the effects of changes in Cu distribution in cells
will be difficult to interpret. Estimates of the dissociation
constants of Cu-ligand interactions make it likely that the ki-
netics of (slow) dissociation steps and protein-protein inter-
actions control many changes in intracellular Cu (see Banci
et al. (2) for discussion). The apparent dissociation constants
for Cu(I) binding proteins and low molecular weight ligands
are, for the intracellular chaperones 2–20  1015 M, and
glutathione (GSH, see below) ~1  1011 M. However,
there is also some debate on the best methods to determine
the Cu affinities for a range of cellular Cu-binding species
(3). These factors also complicate issues in developing re-
agents for monitoring Cu, already addressed a couple of de-
cades ago, in searching for optical indicators to record
changes in the low, but measurable resting cellular Ca con-
centration (~100 nM). In the case of Cu, (at <1018 M) it is
particularly challenging to produce indicators that report on
the Cu(I) status and do so without inherent disruption of the
intracellular Cu distribution. An excellent authoritative re-
view has recently appeared that describes progress that
has been made in this area (4). The sizes of the fluxes
involved physiologically in Cu homeostasis enter new terri-
tory for those interested in transport physiology and
biophysics. Comparison of Na and Cu handling in humans
illustrates this. Kidneys filter ~90 L of plasma every 12 h,
containing 150 mM Na (or ~310 g), of which >95% is reab-
sorbed, largely driven by Na pump fluxes. The turnover rate
for the Na pump is ~120 s1 or ~360 Na ions per second. In
comparison, the total body Cu content is ~100 mg and the
daily dietary intake is ~1–2 mg. Thus, cellular fluxes ofhttp://dx.doi.org/10.1016/j.bpj.2015.11.025
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ing a relatively slow transporter (around 5–10 Cu ions per
transporter trimer per second (5), see below) and low copy
numbers, for example ~1000 endogenous hCTR1 (human
copper transporter 1), trimers per human embryonic kidney
(HEK) cell (5). However, size is not everything!Cellular copper homeostasis
Cu homeostasis is controlled by transporters for the uptake
and effluxofCu ions and thegroups of intracellularmolecules
engaged in handling Cu and delivering it to its specific sites
(see Fig. 1). The efflux transporters are Cu-activated P-type
ATPases, ATP7A and ATP7B, also known asMenkes disease
protein and Wilson disease protein, respectively, for their
associated human genetic diseases. These Cu pumps reside
in the trans-Golgi membranes where they insert Cu into
Cu-dependent enzymes in the secretory pathway.When intra-
cellular Cu is elevated they provide a protective response by
trafficking to the plasma membrane in vesicles, into which
excess Cu has been pumped, which is then ejected from the
cell via exocytosis. When cellular Cu falls they recycle
back to the Golgi. The roles of the Cu transporters in Cu ho-
meostasis has been the subject of several reviews (6,7)
Because free Cu is not found in cells, intermediaries, the
copper chaperones (8), deliver the metal ion to its specific
targets. Studies in yeast provided candidates for these func-
tions and mammalian and human orthologs were subse-
quently identified. There is a specific chaperone that
delivers Cu to the ATPases, termed ATOX1 or HAH1,
another delivers Cu in the synthesis of cytochrome C oxi-
dase, termed Sco1, and to SOD, called copper chaperone
for SOD (CCS). It has been observed that the target enzymes
are not always completely dependent on the chaperones forFIGURE 1 Copper homeostasis in human cells. Cu enters via hCTR1 and
is handed off to copper chaperones, ATOX1, CCS, and COX17, which then
deliver Cu to its target proteins. MT, metallothionein may serve as a storage
site. The efflux proteins, ATP7A and ATP7B, reside in the trans-Golgi and
secretory pathway and relocate via vesicle trafficking and fusion, in condi-
tions of high intracellular Cu, to the plasma membrane.
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the uptake transporter or from GSH (see below). Additional
functions for the chaperones may exist as Cu-dependent
transcription factors (9) or as redox regulators to maintain
appropriate reductive states of sulfhydryls on proteins
involved in Cu homeostasis (10).
The cycling between the Cu(I) and Cu(II) valence states
plays an important role in the Cu-dependent enzymes, but
it is the Cu(I) form that is transported by the major uptake
pathway in mammalian cells. This is based on the homol-
ogies between the yeast and human proteins and the evi-
dence in yeast linking the FRE (iron reductase) genes to
Cu uptake (8,11) as well as x-ray absorbance fluorescence
spectroscopy studies on recombinant hCTR1 (12). It is
also clear from x-ray absorbance fluorescence spectroscopy
studies that copper chaperones, such as CCS bind and
deliver Cu(I) to their target proteins (13). Ag inhibits Cu up-
take (14) and is the only other ion known to be transported
by hCTR1.Copper entry pathways
The ctr proteins, responsible for the high affinity uptake of
Cu, were first identified in the yeast Saccharomyces cerevi-
siae (15,16). Subsequently, the human protein hCTR1
(SLC31A1) was identified by rescue of the yeast mutants
lacking endogenous Cu transporters (17). The mouse homo-
log was next identified and sequenced and is 92% identical
with hCTR1 (18). However, in work on Cu uptake in cells
lacking hCTR1, ~15–20% of the Cu uptake remained and
so other minor transport systems are probably present
(14). There are two plausible candidates. These are,
DMT1, the divalent metal ion transporter that mediates
the uptake of Mn and Zn. Although it has been claimed
that DMT1 can also transport Cu(I) or Cu(II) any significant
role for DMT1 in Cu transport remains to be established
(19). The other candidate(s) for mediating Cu entry emerged
from studies on heterologously expressed hCTR1 in
mammalian cells (20,21). In simple salt buffers there was
such a high rate of Cu entry, that the effect of overexpression
of hCTR1 on the Cu uptake rate was quite small. On the
addition of serum, or agents that coordinate Cu, the total up-
take was lowered and the major contribution of hCTR1 was
evident. In the absence of ligands that coordinate Cu, there
was a high rate of 4,4’-diisothiocyano-2,2’-stilbenedisul-
fonic acid-inhibited Cu entry, independent of the presence
or absence of hCTR1 (21). The mechanism is suggested
by work in erythrocytes, showing that high rates of Cu up-
take were inhibited by 4,4’-diisothiocyano-2,2’-stilbenedi-
sulfonic acid, and occurred via Band III, or AE1, the
anion exchanger (22). Metal ions were transported as metal-
loanion complexes of the [MnCl]n-2- or [MClOH]n-1-types.
A detailed discussion of this has appeared (21). In specific
locations (duodenal lumen, for example) where pH is low
and Cu ligands are protonated or absent, there may be a
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This may be relevant in the intestine, where entry mecha-
nisms for Cu at the apical surface are still uncertain (7).
For most cells, bathed in serum, ~90% of Cu uptake is medi-
ated by hCTR1. Previous reviews described structure-mech-
anism relations of hCTR1 (23) and the roles of the CTR
family of Cu transporters in health and disease (24). We
will now discuss current ideas about the structure, mecha-
nism, and roles of hCTR1 in Cu acquisition and regulation.hCTR1: sequence and structure
The first sequenced mammalian high affinity Cu transporters
were the human (17) and mouse proteins (18) that contain
several characteristic features (23). hCTR1 consists of 190
amino acids and several regions with putative metal binding
sequences, rich in Met and His. The monomeric polypeptide
was proposed to have three transmembrane segments (Fig. 2).
Two putative extracellular N-linked glycosylation sites on
opposite sides of the first transmembrane segment enabled
the membrane topology to be assigned by the demonstration
that extensive N-linked glycosylation occurred at Asn-15
(25) (see Fig. 1). hCTR1 also has short O-linked glycosyla-
tion at Thr-27 that protects the amino-terminus against cleav-
age by intracellular proteases (26). The proteolytic product
obtained when O-linked glycosylation is prevented is a less
efficient transporter than the full-length protein.
The small size of the monomeric protein made it likely
that the functional unit was an oligomeric form of the pro-
tein (14,15,25,27) and this was confirmed in the cryoelec-
tron structure of unglycosylated hCTR1, obtained by
overexpression in Pichia pastoris (28). The structure shows
a trimer with a central pore, which presumably forms aFIGURE 2 Sequence, topology, and key residues of hCTR1 monomer.
The 190 amino acid polypeptide spans the membrane three times. The po-
tential Cu-coordinating residues are shown, Met in red and Cys in blue. The
two putative N-linked glycosylation sites are shown in yellow. Extracellular
N-glycosylation occurs at Asn-15, O-linked glycosylation occurs at Thr-27.transmembrane pathway for Cu ions. A full three-dimen-
sional crystallographic structure at 7 A˚ subsequently re-
vealed a central pore spanning the width of the membrane.
The second transmembrane segments of each monomer
line the central pore. The pore has a conical structure with
an outer diameter of ~8 A˚, widening to ~22 A˚ at the cyto-
plasm (12). The acquisition of structures set the stage for
targeted mechanistic studies using mutagenic analysis of
hCTR1 that have revealed many interesting features of
this unique system.hCTR1: mechanism of transport
A model for hCTR1-mediated Cu transport emerged from a
series of studies on mutations of hCTR1 and their effects on
yeast growth in a strain lacking endogenous yeast trans-
porters (18), isotopic Cu64 uptake in baculovirus-infected
insect cells (29) or in stably transfected mammalian cells
(5). The extracellular amino-terminus, containing several
MXXM sequences, is involved in the initial interaction
with Cu (or Cu with its serum carrier) and probably delivers
the Cu to the pore (30). The sequence of the amino-terminus
is not highly conserved across species, although they all
contain putative Cu-binding sequences, suggesting similar-
ities in mechanistic significance. Removal or substitution
of several of these segments does not greatly affect trans-
port, only the Met residues closest to the membrane
(Met-43 and Met-45 in hCTR1) are essential for Cu uptake
(30). A computational all-atom model of hCTR1, proposed
that the Met-rich sequences in the amino-terminus form
stacked rings that guide the Cu ions into the pore (31)
(Fig. 3). Two rings of essential Met residues (Met-150 and
Met-154), at the entrance to the pore are important in theFIGURE 3 Cartoon of trimeric transporter based on an all-atom model
(see Tsigelny et al. (31)). Each monomer of the active trimer are shown
in red, cyan, or purple. The putative Cu-coordinating residues, extracellular,
Met-43, Met-45, intramembrane, Met-150, Met-154, and intracellular His-
188-Cys-189-His-190, in green. His-139 is shown in blue. The conical pore
is shaded. Left panel view from side, right panel view from extracellular
aspect.
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FIGURE 4 hCTR1 is internalized in the presence of elevated medium
Cu. Live-cell imaging of HEK 293 cells expressing CLIP-labeled hCTR1
(red) in the presence or absence of 50 mM Cu. In the absence of Cu
hCTR1 is seen predominantly at the plasma membrane. In the presence
of Cu, much of the hCTR1 is internalized. via endocytosis.
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a selectivity filter. Replacement of these Met residues by
Leu, which cannot coordinate Cu, shuts off transport (30).
Following coordination by the Met triads, Cu ions enter
the pore and then emerge at the cytosolic aspect of the
pore. The interactions between the Cu ions and the protein
during the transport process remain elusive.
The highly conserved intracellular carboxyl-terminus of
15 amino acid residues is completely conserved among
mammalian species and contains a terminal His-Cys-His
sequence that, in principle, is able to coordinate Cu ions.
A structural study suggested a key role for this terminal
sequence (12). It was concluded that Cu binding occurred
at this terminal sequence, through the three Cys-189 resi-
dues of the trimeric transporter. Furthermore, it was sug-
gested that the higher affinity binding at this site,
compared to the Met triads at the pore entry, provides the en-
ergetic difference necessary for transport. This proposal had
the attractive quality of supplying an essential mechanistic
and energetic role for the highly conserved putative terminal
Cu binding sequence, His-Cys-His.
More recent observations suggest that this model does not
provide an accurate picture of the Cu transport process. We
have recently shown that substitution of the terminal His-
Cys-His sequence byAla-Ala-Ala results in aCTR1molecule
with a significantly higher maximal rate of transport
(expressed per trimeric transporter, the turnover number is
~5 Cu ions per second for wild-type compared with ~17 Cu
ions per second for the Ala-substituted mutant) (5). Not
only is Cu binding at the intracellular terminal sequence not
necessary, but the presence of the His-Cys-His sequence
slows, rather than facilitates transport. The ability to bind
Cu ions at this terminal site does not enable or drive transport,
but actually lowers the transport rate. Not only is the presence
of the sequence at the tail important for thismodulatory effect,
but if its spatial position is altered, by shortening the extra-
membrane length, through upstream deletions, it also fails
to lower the transport rate (E.B.M. and J.H.K., unpublished
data). All mutational changes that elevate the maximal rate
of transport also increase the Km for transport of Cu (5).
A similar functional effect, an increase in transport rate, has
been reported to occur when the C-terminal tail of the yeast
ctr1 is deleted (32). However, the cytoplasmic C-terminal
tail of the yeast protein consists of >100 residues, whereas
hCTR1has only 15, so that themechanistic basis of the similar
effect is not clear. A related effect, first seen in the insect cell
system and subsequently confirmed in mammalian cells em-
phasizes the importance, of ion-pore interactions. Replace-
ment of His-139, in the second transmembrane segment by
Arg, also results in an increased rate of transport (turnover
number ~18 Cu ions per second, per trimer) (5). It is not clear
if this modification results in a weakening (via Arg-Cu charge
repulsion effects) of Cu interactions with the pore during
transit, or if interactions between the three Arg residues (one
from each monomer) cause a distortion of the pore. It hasBiophysical Journal 110(1) 7–13been pointed out previously that hCTR1 is unlikely to be a
simple pore (28) and earlier evidence suggests that the binding
of Cu causes conformational changes in the protein (25).hCTR1: regulation of Cu entry by acute alterations
in surface expression
When extracellular Cu is elevated the transporter is internal-
ized (33). This observation offered a plausible mechanism
whereby cells might protect themselves against excess Cu
entry. Internalization would lead to a regulatory decrease
in influx in response to elevated extracellular Cu, in a similar
fashion to the increase of Cu efflux (in response to elevated
intracellular Cu) by trafficking Cu-activated ATPases to the
plasma membrane from intracellular compartments. Recent
studies have confirmed that indeed in the face of elevated
levels of extracellular Cu, cells protect themselves against
the potential adverse effects of Cu overload by rapidly
(and reversibly) lowering Cu entry rates (34). This is accom-
plished by what we have termed regulatory endocytosis. In
this mechanism, when medium Cu is raised, endocytosis of
hCTR1 occurs and hCTR1 is internalized (Fig. 4). When
extracellular Cu is lowered, the transporter recycles back
to the plasma membrane. These processes do not involve
new protein synthesis and provide an acute regulatory
response to increases in the Cu load (34). Although this pro-
cess is still the subject of investigation several interesting
findings have emerged. When extracellular Cu is raised
hCTR1 is internalized rapidly (in several minutes). If the
exposure to elevated Cu is not prolonged (~30 min or
less), lowering of the extracellular Cu results in the return
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45 min) and the recovery of the rate of Cu uptake (34).
Recent studies have shown that the internalization is cla-
thrin- and dynamin-dependent (R.J. Clifford, E.B.M., and
J.H.K., unpublished data). It is possible that extended expo-
sure to elevated Cu results in some degradation, but acute
treatments result in full recovery.
A mechanism that might account for this Cu-dependent
endocytosis would be that a lower affinity site (lower than
the key binding site for transport) binds Cu and causes a
conformational change in an internal aspect of hCTR1 that
enables the transporter to engage with the cellular protein
import machinery. Thus, a critical Cu-bound conformation
is key to the internalization process. In the course of
analyzing Cu uptake kinetic properties of an array of
hCTR1 mutants we have observed that, strikingly, those mu-
tants in the carboxyl-terminus, where the His-Cys-His
sequence is removed, that cause an elevated rate of Cu up-
take, fail to undergo Cu-dependent endocytosis (5). This im-
plies that Cu binding to this His-Cys-His site triggers
interaction with the import machinery. Alternatively, an in-
termediate in the transport cycle, with extra Cu bound to
the transporter interacts with the import machinery, and in
the more rapidly transporting forms of hCTR1, the dwell
time of the key intermediate is too small to allow the interac-
tion that enables endocytosis. The particular and specific
involvement of the carboxyl-terminus is quite provocative,
but the observation that His-139, a pore mutant with an
elevated maximal transport rate, also fails to undergo endo-
cytosis, suggests that the interaction of hCTR1 with the pro-
tein import machinery includes more than just the carboxyl-/
terminal sequence or perhaps faster than normal transport
cycling, whatever the cause, impedes internalization.FIGURE 5 Glutathione as the initial acceptor. Glutathione, a small tri-
peptide (orange) picks up the Cu(I) ions as they exit hCTR1 and delivers
them to the chaperones, CCS and ATOX1.hCTR1: intracellular Cu delivery
The transfer of Cu to intracellular chaperones, via direct
interaction with hCTR1, has been proposed as a key step
in cellular Cu homeostasis. Recent modeling and docking
scenarios, together with some immunoprecipitation data
supported this notion (35). However, the idea that the inner
face of hCTR1 would interact specifically with several
structurally unrelated metallochaperones, each of which
would then deliver the Cu specifically to a target protein
has always raised some questions about how this might be
achieved. In studies performed before the discovery of the
Cu chaperones, using biochemical fractionation it was
found that the initial intracellular Cu-binding moiety was
glutathione (GSH, g-glutamyl-cysteinyl-glycine), an endog-
enous Cu-coordinating molecule present in high abundance
(often 3–5 mM) in eukaryotic cells (36).
If handing off Cu from hCTR1 to the chaperones is the
final step in the transport process, then large alterations in
chaperone levels should influence the rate of uptake. In
HEK cells that overexpress hCTR1 (or with endogenoushCTR1), we showed that substantially knocking down or
overexpressing ATOX1, CCS, or both, had no effect on
the Cu uptake rate (37). However, lowering GSH levels by
~95% (from 4 mM) by inhibition of GSH synthetase, caused
a 50% reduction in the rate of Cu uptake. The uptake rate
could be recovered by replenishment of GSH. We suggested
that the initial intracellular acceptor at the intracellular face
of hCTR1 is GSH. The Cu:GSH complex then delivers Cu
to the chaperones. The reversible inhibition of Cu uptake
by lowering GSH was demonstrated in a number of other
mammalian cells (37). That GSH is the initial Cu acceptor
finds support in reported measurements of Cu affinities of
the chaperones and GSH, which suggested that GSH was
poised by virtue of its relative affinity to act as the initial
cellular Cu acceptor and to hand it off to the chaperones
(2). A comparison of the relative copy numbers of the chap-
erones, GSH and hCTR1 in cells shows that GSH is favored
over the chaperones by >4 orders of magnitude for interac-
tion with hCTR1 (5). The effects on the rate of Cu uptake,
when GSH is lowered or replenished, are seen with
hCTR1 mutants lacking the terminal putative metal-binding
sequence motif, so that this putative metal-binding site plays
no essential role in transfer to GSH. Our favored model
currently is that hCTR1 hands off Cu to GSH, a high capac-
ity, low affinity buffer that acts as donor to the chaperones
(Fig. 5).A second CTR protein in human cells
In the original yeast complementation studies a second gene
member of the human CTR proteins was cloned. Its similar-
ity to hCTR1 was noted and the suggestion made that
hCTR2 was also a Cu transporter (17). CTR2 lacks theBiophysical Journal 110(1) 7–13
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thought to be important for transport are conserved, along
with the basic membrane topology. It has been suggested
that CTR2 is predominantly an intracellular Cu transporter
(38,39), can apparently perform Cu transport when over-
expressed (40), and interestingly may play a role in targeting
hCTR1 for degradation (41). Its major physiological func-
tions remain unresolved and await more systematic
investigation.Unresolved questions
We pointed out, ~8 years ago that not only was Cu homeo-
stasis important physiologically and Cu transport interesting
biophysically, but most of the important issues were unre-
solved (42). This remains true and progress has been
made. hCTR1 is a very interesting and novel transporter,
by virtue of its trimerization to form a pore structure that
mediates cellular uptake of a substrate only present at
very low levels in the circulation. We pointed out that the
identity of the major source of available Cu in the circula-
tion, which donated Cu to hCTR1 was unknown; this is still
true. The identity of the initial intracellular acceptor was un-
known; now there is evidence that supports the notion of a
common acceptor, GSH. The precise role of the extracel-
lular amino-terminus was unknown, other than presumably
to interact with the extracellular donor. This uncertainty re-
mains. Meanwhile, the importance of the intracellular
carboxyl-terminus has received increasing attention, as it
seems to act as a modulator of transport, and also is essential
for the protein to undergo regulatory endocytosis. The
mechanism of transport has been probed using ideas gleaned
from the behavior of other better-characterized transporters
and appears to combine elements of channels and trans-
porters. An alternate and provocative possibility remains.
hCTR1 may function in a novel way, essentially providing
an intramembrane scaffold that enables coordination of Cu
at the mouth of a pore allowing access of intracellular
GSH to carry out a ligand-exchange reaction, plucking Cu
from the Met triad coordinating center and delivering it to
the cytosol.
It is clear that the acquisition of Cu by cells is far from
being well understood and that its cellular uptake and ho-
meostasis have evolved a complex network of interactions
among a fascinating assembly of players. A detailed under-
standing of these processes will require the application of an
array of biophysical approaches.REFERENCES
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